Featured Research

from universities, journals, and other organizations

New funding for development of mucosal vaccines based on nanoparticle technology

Date:
October 8, 2013
Source:
University of Gothenburg
Summary:
New funds have been invested into the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Researchers wil combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

According to world-health organizations, vaccination programs against the most serious infectious diseases represent the single-most important measure to improve global health and prevent debilitating disease. However, as most vaccines are injected and given by highly-trained healthcare personnel they are more difficult to administer in many parts of the world and the use of syringes, which may be reused, increases the risk for blood born contamination and spread of infection.

Also traditional mass vaccination in case of pandemic spread of infection, as for example with influenza, is very costly and difficult to undertake with traditional vaccines.

Mucosal vaccines, drinkable or nasal spray vaccines, have many practical advantageous, but few mucosal vaccines are commercially available today. This is because mucosal vaccines need powerful adjuvants and finding effective formulations that protect the vaccine components from degradation in harsh mucosal environments, such as the gut intestine.

The adjuvant is the critical component of most vaccines that greatly enhances the immune response. For mucosal vaccines traditional adjuvants are not effective. Another advantage of mucosal vaccines is that the immune defense is located to the mucosal membranes that are the port of entry for most pathogens, including tuberculosis, influenza and HIV.

The research team has received funding from the Foundation to develop the next generation of effective mucosal vaccines based on their expertise in vaccine adjuvant and lipid nanoparticle research.

"We are now taking a unique and pioneering step towards a universal platform for mucosal vaccines by developing a new targeted lipid nanoparticle vaccine that combines knowledge from different disciplines," says Nils Lycke.

The team of researchers to undertake the project are professors Nils Lycke and Mary-Jo Wick at the Sahlgrenska Academy, William Agace at Lund University, Fredrik Höök and Marta Bally at Chalmers.

The research group will take a conceptually new approach to combining effective adjuvants with lipid nanoparticles to direct these complexes to the dendritic cells in the mucosal membranes.

These cells are the key target for the next generation of mucosal vaccines and responsible for initiating vaccine immune responses. The researchers have complementing expertise to solve the problems of how to combine all the expected properties of the mucosal vaccine in one particle.

"Thanks to a flexible particle design, and extensive experience with a patented adjuvant system we hope to be successful in our efforts" says Nils Lycke. If successful, the next generation of mucosal vaccines will have a major impact not only on vaccine prevention of infections, but also on global health " says Nils Lycke.

"The idea is unique in several respects. No one has previously combined these components in a particle and no one has, in a structured manner, optimized the lipid particles to make mucal inoculations effective."

The research project brings together four internationally successful research leaders with expertise in immunology, nano-biotechnology and vaccine development.


Story Source:

The above story is based on materials provided by University of Gothenburg. Note: Materials may be edited for content and length.


Cite This Page:

University of Gothenburg. "New funding for development of mucosal vaccines based on nanoparticle technology." ScienceDaily. ScienceDaily, 8 October 2013. <www.sciencedaily.com/releases/2013/10/131008102356.htm>.
University of Gothenburg. (2013, October 8). New funding for development of mucosal vaccines based on nanoparticle technology. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/10/131008102356.htm
University of Gothenburg. "New funding for development of mucosal vaccines based on nanoparticle technology." ScienceDaily. www.sciencedaily.com/releases/2013/10/131008102356.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins